Pigmentation disorders are a big concern widely shared by most of the populations (Asian, African, Latin-American people). Among benign pigmentation disorders, some are stimulated by ageing (freckles, lentigines and melasma) and stress (inflammatory hyperpigmentation).
Sederma is offering a new solution to people wishing to reduce irregularities in pigmentation or to lighten their skin complexion. Based on a botanical, it acts on both melanocytes and their associated keratinocytes to help lessen pigmentation disorders. It disrupts the Epidermal Melanin Unit cross-talking and blocks the signalling pathways involved in the melanin synthesis. Wonderlight exhibits a stronger effect on hyper pigmented areas and equalises skin pigmentation in order to make them less visible. The ability of the new product to inhibit the UV-inducted secretion of GM-CSF (important melanocyte stimulator) was demonstrated in vitro. The concept was validated on living human skin cultures (phototype III) in which the UVAB induced two-fold increase in the number of melanocytes was totally inhibited in the presence of Wonderlight. Two clinical trials conducted on Asian volunteers with classical pigment disorders (lentigines, ephelides, melasma, postinflammatory hyperpigmentation) confirmed the melanogenesis reducing activity of Wonderlight on these lesions. Wonderlight is preservative free and is approved for Japan.
